Unilateral Prostate Cancer Cannot be Accurately Predicted in Low-Risk Patients

Hendrik Isbarn, Pierre I. Karakiewicz, Susanne Vogel, Claudio Jeldres, Giovanni Lughezzani, Alberto Briganti, Francesco Montorsi, Paul Perrotte, Sascha A. Ahyai, Lars Budäus, Christian Eichelberg, Roman Heuer, Jens Köllermann, Guido Sauter, Thorsten Schlomm, Thomas Steuber, Alexander Haese, Mario Zacharias, Margit Fisch, Hans HeinzerHartwig Huland, Felix K H Chun, Markus Graefen

Research output: Contribution to journalArticlepeer-review


Purpose: Hemiablative therapy (HAT) is increasing in popularity for treatment of patients with low-risk prostate cancer (PCa). The validity of this therapeutic modality, which exclusively treats PCa within a single prostate lobe, rests on accurate staging. We tested the accuracy of unilaterally unremarkable biopsy findings in cases of low-risk PCa patients who are potential candidates for HAT. Methods and Materials: The study population consisted of 243 men with clinical stage ≤T2a, a prostate-specific antigen (PSA) concentration of

Original languageEnglish
Pages (from-to)784-787
Number of pages4
JournalInternational Journal of Radiation Oncology Biology Physics
Issue number3
Publication statusPublished - 2010


  • Hemiablative therapy
  • Prostate biopsy
  • Prostate cancer
  • Radical prostatectomy
  • Unilateral

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation
  • Cancer Research


Dive into the research topics of 'Unilateral Prostate Cancer Cannot be Accurately Predicted in Low-Risk Patients'. Together they form a unique fingerprint.

Cite this